Sexual HealthFDA ApprovedS

PT-141

Bremelanotide / Vyleesi

PT-141 (bremelanotide, brand: Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, PT-141 acts centrally on melanocortin receptors in the CNS to increase sexual desire and arousal rather than acting peripherally on blood flow. Administered as a subcutaneous autoinjector 45 minutes before anticipated sexual activity. Banned from 503A compounding pharmacies.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
4
Research grade
S
Community score
120

Trend index

Trackers
2,013

Overview

About PT-141

PT-141 (bremelanotide, brand: Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, PT-141 acts centrally on melanocortin receptors in the CNS to increase sexual desire and arousal rather than acting peripherally on blood flow. Administered as a subcutaneous autoinjector 45 minutes before anticipated sexual activity. Banned from 503A compounding pharmacies.

Category
Sexual Health
Regulatory status
FDA Approved
Also known as
Bremelanotide / Vyleesi
Self-reports
27

Community

What 27 users report

27 community reports

Positive 3% · Neutral 2% · Negative 95%

Most reported benefits

Libido
113

Most reported side effects

Nausea
38
Headache
37
Injection site irritation
35

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
0
25–50
0
50–100
0
100–200
1
200–400
2
400–600
9
600–1000
3
1000–2000
8
2000+
90

How repeat users are trending

Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 100 days · Based on 23 repeat reporters

Research

Cited research (2)

FDA Drug Label

VYLEESI (bremelanotide injection) for subcutaneous use - Prescribing Information

AMAG, 2019

Source
Wiki study page →

Help

Frequently asked

What do PeptIQ users report about PT-141?

This page summarizes 27 anonymized self-reports from PeptIQ users who track PT-141, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for PT-141?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is PT-141 safe to use?

This wiki does not assess safety or recommend use. PT-141 is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of PT-141?

Research, primarily in animal models, suggests PT-141 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of PT-141?

PT-141 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified PT-141 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of PT-141?

The safety and effectiveness of PT-141 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on PT-141?

While there are over 200 published studies on PT-141, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source